{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:28:45Z","timestamp":1794641325922,"version":"4.9.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01324-7","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T20:26:22Z","timestamp":1751574382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine\u2013venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0035-8657","authenticated-orcid":false,"given":"Minoru","family":"Kanaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-2864","authenticated-orcid":false,"given":"Masahiro","family":"Onozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5270-0362","authenticated-orcid":false,"given":"Fumiaki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Senjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0099-225X","authenticated-orcid":false,"given":"Tetsuyuki","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Ebata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Iyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Oyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-5824","authenticated-orcid":false,"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"1324_CR1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1080\/10428194.2021.2002321","volume":"63","author":"T Miyamoto","year":"2022","unstructured":"Miyamoto T, Sanford D, Tomuleasa C, Hsiao HH, Olivera LJE, Enjeti AK, et al. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy. Leuk Lymphoma. 2022;63:928\u201338.","journal-title":"Leuk Lymphoma"},{"key":"1324_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1324_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100017","volume":"1","author":"J Othman","year":"2024","unstructured":"Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, et al. Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS. Blood Neoplasia. 2024;1:100017.","journal-title":"Blood Neoplasia"},{"key":"1324_CR4","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1182\/blood-2024-198943","volume":"144","author":"M Kanaya","year":"2024","unstructured":"Kanaya M, Mukai Y, Kobayashi M, Kajikawa S, Suzuki T, Yokoyama E, et al. Combination of low white blood cell count and impaired renal function is a risk factor for higher concentrations of venetoclax and prolonged neutropenia in AML patients with venetoclax combined regimen: real-world experience in the Japanese cohort. Blood. 2024;144:2930.","journal-title":"Blood"},{"key":"1324_CR5","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1002\/ajh.27180","volume":"99","author":"O Karrar","year":"2024","unstructured":"Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A, et al. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival. Am J Hematol. 2024;99:E63\u2013E66.","journal-title":"Am J Hematol"},{"key":"1324_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba M, Shigematsu A, Suzuki T, Miyagishima T. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol. 2023;102:541\u20136.","journal-title":"Ann Hematol"},{"key":"1324_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01269-x","volume":"15","author":"C Willekens","year":"2025","unstructured":"Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, et al. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J. 2025;15:68.","journal-title":"Blood Cancer J"},{"key":"1324_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01270-4","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Tefferi A. Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days. Blood Cancer J. 2025;15:56.","journal-title":"Blood Cancer J"},{"key":"1324_CR9","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/bjh.19292","volume":"204","author":"N Miyashita","year":"2024","unstructured":"Miyashita N, Onozawa M, Matsukawa T, Mori A, Hidaka D, Minauchi K, et al. Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study. Br J Haematol. 2024;204:1549\u201353.","journal-title":"Br J Haematol"},{"key":"1324_CR10","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1324_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99:193\u2013202.","journal-title":"Am J Hematol"},{"key":"1324_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ajh.27564","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, et al. Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax + hypomethylating agent. Am J Hematol. 2025;100:260\u201371.","journal-title":"Am J Hematol"},{"key":"1324_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ajh.27256","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Tefferi A. Venetoclax in the treatment of acute myeloid leukemia: beyond VIALE-A. Am J Hematol. 2024;99:515\u20138.","journal-title":"Am J Hematol"},{"key":"1324_CR14","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","volume":"145","author":"AH Wei","year":"2025","unstructured":"Wei AH, Loo S, Daver N. How I treat patients with AML using azacitidine and venetoclax. Blood. 2025;145:1237\u201350.","journal-title":"Blood"},{"key":"1324_CR15","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1182\/blood-2024-210967","volume":"144","author":"U Borate","year":"2024","unstructured":"Borate U, Huang Y, Zeidner JF, Swords RT, Koenig KL, Stein EM, et al. A randomized phase 2 trial of 28-day (Arm A) versus 14-day (Arm B) schedule of venetoclax + azacitidine in newly diagnosed acute myeloid leukemia patients \u2265 60 years. Blood. 2024;144:2907.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01324-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01324-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01324-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T20:26:23Z","timestamp":1751574383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01324-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01324-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MK's spouse is an employee of AbbVie GK. TK has received honoraria from Astellas Pharma, AbbVie, Amgen, Kyowa Kirin, Nippon Shinyaku, Ono Pharmaceutical, Otsuka Pharmaceutical, Novartis, Pfizer, and Bristol-Myers Squibb; and consultancy fees from Otsuka Pharmaceutical. TT has received honoraria from Abbvie, Astellas, AstraZeneca, Novartis, Bristol-Myers Squibb, Gilead, Nippon Shinyaku, Kyowa Kirin, Janssen, and research funding from LUCA Science, Priothera SAS, Pharma Essentia Japan, Abbvie, IQVIA, CSL Behring, Cmic, Gilead, Novartis, Janssen, Chugai, Kyowa Kirin, International Advanced Medical Organization, and subsidy or donation from Chugai, Kyowa Kirin, Sumitomo Pharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}